December 06, 2020
Based on a median follow-up of four years, John Allen, MD, assistant professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine, New York-Presbyterian Hospital, explains how first-line ibrutinib-based treatment resulted in sustained efficacy with high progression-free survival and overall survival rates in CLL patients with TP53 aberrations—a population with historically poor outcomes.
Allen JN, Shanafelt T, Wiestner A, et al. Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials (Abstract 2219) https://ash.confex.com/ash/2020/webprogram/Paper134431.html. December 6, 2020.